Bookman Michael 4

Accession 0001628280-24-024953

CIK 0001790340other

View on SEC.gov Company Profile

Filed

May 22, 8:00 PM ET

Accepted

May 23, 4:20 PM ET

Size

21.8 KB

Accession

0001628280-24-024953

Insider Transaction Report

Form 4

Period: 2024-05-21

Immuneering CorpIMRX

Bookman Michael

CHIEF LEGAL OFFICER, SECRETARY

Transactions

Award
Stock Option
2024-05-21+101,116→ 101,116 total
Exercise: $3.01Exp: 2031-07-28→ Class A Common Stock (101,116 underlying)
Award
Stock Option
2024-05-21+47,300→ 47,300 total
Exercise: $3.01Exp: 2032-02-09→ Class A Common Stock (47,300 underlying)
Disposition to Issuer
Stock Option
2024-05-21−47,300→ 0 total
Exercise: $9.66Exp: 2032-02-09→ Class A Common Stock (47,300 underlying)
Disposition to Issuer
Stock Option
2024-05-21−101,116→ 0 total
Exercise: $15.00Exp: 2031-07-28→ Class A Common Stock (101,116 underlying)
Disposition to Issuer
Stock Option
2024-05-21−143,000→ 0 total
Exercise: $4.25Exp: 2033-02-15→ Class A Common Stock (143,000 underlying)
Award
Stock Option
2024-05-21+143,000→ 143,000 total
Exercise: $3.01Exp: 2033-02-15→ Class A Common Stock (143,000 underlying)
Disposition to Issuer
Stock Option
2024-05-21−93,000→ 0 total
Exercise: $6.09Exp: 2034-02-08→ Class A Common Stock (93,000 underlying)
Award
Stock Option
2024-05-21+93,000→ 93,000 total
Exercise: $3.01Exp: 2034-02-08→ Class A Common Stock (93,000 underlying)

Footnotes (5)

[F1]On May 21, 2024, the Issuer's Board of Directors approved an option repricing (the "Repricing") whereby the Reporting Person's options were repriced to an exercise price of $3.01 per share. Under the terms of the Repricing, unless there is a change of control of the Issuer, the exercise price for the repriced options will revert to the original exercise price of the option if, prior to June 30, 2025, the Reporting Person: (i) is terminated by the Issuer for cause or resigns from the Issuer, except by reason of death or disability; or (ii) elects to exercise the repriced options. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.
[F2]The option vests and becomes exercisable as to 25% of the underlying shares on July 15, 2022 and then in equal monthly installments over the subsequent three years, subject to Mr. Bookman's continued employment through each applicable vesting date.
[F3]The option vests and becomes exercisable in equal monthly installments over a four-year period commencing on February 1, 2022, and will be fully vested and exercisable on January 1, 2026.
[F4]The option vests and becomes exercisable in equal monthly installments over a four-year period commencing on February 1, 2023, and will be fully vested and exercisable on January 1, 2027.
[F5]The option vests and becomes exercisable in equal monthly installments over a four-year period commencing on February 1, 2024, and will be fully vested and exercisable on January 1, 2028.

Documents

1 file

4
wk-form4_1716495592.xmlPrimary
FORM 4

Issuer

Immuneering Corp

CIK 0001790340

→

Entity typeother

Related Parties

filerCIK 0001840339

Filing Metadata

Form type: 4
Filed: May 22, 8:00 PM ET
Accepted: May 23, 4:20 PM ET
Size: 21.8 KB

View on SEC.gov